证券代码：301370 证券简称：国科恒泰 公告编号：2025-027 国科恒泰（北京）医疗科技股份有限公司 关于举行 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日在巨潮资讯网披露《2024 年年度报告》《2024 年年度报告摘要》及《2025 年第一季度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战 略等情况，公司定于 2025 年 5 月 19 日（星期一）15:00-17:00 举办公司 2024 年度 暨 2025 年第一季度业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意 见和建议。现将有关安排公告如下： 现场会议召开地点：证券日报元宇宙路演中心（北京市西城区车公庄大街 21 号院 39 幢首创新大都 1 号楼 3 层） 网络会议参与方式：投资者可登录证券日报网路演平台（http://www.zqrb.cn/h uiyi/lyhd/index.html）参与本次业绩说明会。 二、 ...

长城证券股份有限公司 关于国科恒泰（北京）医疗科技股份有限公司 2024 年度持续督导现场培训情况报告 长城证券股份有限公司（以下简称"长城证券"或"保荐机构"）作为国科 恒泰（北京）医疗科技股份有限公司（以下简称"国科恒泰"或"公司"）首次 公开发行股票并在创业板上市的保荐机构和持续督导机构，根据《证券发行上市 保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所 上市公司自律监管指引第 13 号——保荐业务》等相关规定，对国科恒泰进行了 2024 年度持续督导现场培训，相关情况如下： 一、培训对象 国科恒泰董事、监事、高级管理人员、中层以上管理人员及公司控股股东和 实际控制人代表等相关人员。 五、培训成果 通过本次培训，使国科恒泰控股股东及实际控制人、董事、监事、高级管理 人员等相关方进一步知晓上市公司治理、募集资金管理和使用、信息披露、大股 东和董监高股份减持等方面的法律法规；知悉上市公司规范运作方面的责任和义 务；进一步明确了作为公司董事、监事、高级管理人员及控股股东和实际控制人 的责任与义务；提高了培训对象 ...

长城证券股份有限公司 关于国科恒泰（北京）医疗科技股份有限公司 2024 年度持续督导定期现场检查报告 （3）查阅公司内部控制评价报告，向公司内审部门人员了解公司内部控制的有效性； | 保荐人名称：长城证券股份有限公司 | 被保荐公司简称：国科恒泰 | | | | --- | --- | --- | --- | | 保荐代表人姓名：张涛 | 联系电话：0755-83516222 | | | | 保荐代表人姓名：李宛真 | 联系电话：0755-83516222 | | | | 现场检查人员姓名：张涛、刘斌、常晋意 | | | | | 现场检查对应期间：2024 年 1 月 1 日至 2024 年 12 月 31 日 | | | | | 现场检查时间：2025 年 月 日、23 日-24 日 4 21 | | | | | 一、现场检查事项 | 现场检查意见 | | | | （一）公司治理 | 是 | 否 | 不适用 | | 现场检查手段： | | | | | （1）查阅公司章程和公司治理相关制度，并访谈董事会秘书了解其执行情况； | | | | | （2）查阅公司股东会、董事会文件及相关信息披露文件； | | | ...

Group 1 - Shengxiang Bio plans to increase its investment in Hunan Shengwei Kunteng Biotechnology Co., Ltd. by 100 million yuan to enhance its industrial chain layout in the POCT field, resulting in a 44.6441% stake in Shengwei Kunteng after the investment [1] - Yaguang Technology's subsidiary Chengdu Yaguang signed a product pre-production agreement worth 101 million yuan, accounting for 10.56% of the company's audited revenue for the last fiscal year [1] Group 2 - Chutianlong's shareholder plans to reduce its stake by up to 3%, equating to 13.83 million shares, due to personal funding needs [2] - Naipu Mining intends to invest up to 45 million USD in Swiss Veritas Resources AG, acquiring a 22.5% stake to extend its industrial chain [2][3] Group 3 - Diri Medical's shareholder plans to reduce its stake by up to 3%, totaling 814.83 thousand shares, due to funding needs [4] - Kangtai Medical's controlling shareholder plans to reduce its stake by up to 2.99%, equating to 12 million shares [5] Group 4 - Iwu Bio's controlling shareholder plans to transfer up to 450 thousand shares through block trading, representing 0.86% of the total share capital [7] - Guokai Hengtai's four shareholders plan to collectively reduce their stake by up to 4.7%, totaling 22.94 million shares [9] Group 5 - *ST Zhongcheng submitted a hearing application to the Shenzhen Stock Exchange in response to a delisting notice [10] - Donghua Software's actual controller and associated parties plan to reduce their stake by up to 1%, totaling 32.05 million shares [12] Group 6 - Shandong Molong's shareholder reduced its H-share holdings by 107 million shares, representing 13.39% of the total share capital [12] - Yinbang Co.'s shareholder plans to reduce its stake by up to 1%, totaling 821.92 thousand shares [13] Group 7 - Jinxinnong reported April sales of 10.65 million pigs, generating sales revenue of 139 million yuan, with an average selling price of 15.05 yuan per kilogram [14] - Dongfang Jiasheng purchased 9.54 million shares of Zhonggu Logistics for approximately 99.72 million yuan, representing 4.18% of the company's net assets [15] Group 8 - Linglong Tire's controlling shareholder received a financing commitment of up to 270 million yuan for stock repurchase [16] - Wuchan Jinlun's shareholder plans to reduce its stake by up to 3%, totaling 619.77 thousand shares [18] Group 9 - Pengyao Environmental's directors and executives plan to collectively reduce their stake by up to 0.07% [19] - Ruihu Mould's controlling shareholder plans to reduce its stake by up to 1.92%, totaling 401.89 thousand shares [20] Group 10 - Electric Alloy's shareholder plans to reduce its stake by up to 0.63%, totaling 210.88 thousand shares [22] - Shanghai Xinyang's controlling shareholder plans to reduce its stake by up to 0.64%, totaling 200 thousand shares [24] Group 11 - Sujiao Ke's controlling shareholder plans to acquire up to 2% of the company's shares from a fund [26] - Heyuan Bio's shareholders plan to reduce their stake by up to 1%, totaling 649.04 thousand shares [27]

Group 1 - The issuance scale of equity funds in China has exceeded 50% of the total new fund issuance in 2025, with a total of 340 billion yuan, marking a significant increase compared to previous years [1] - The People's Bank of China and the China Securities Regulatory Commission have announced support for the issuance of technology innovation bonds, leading to a surge in issuance plans from various financial institutions and enterprises, with a total issuance scale exceeding 210 billion yuan [1] - The recent drop in housing provident fund loan rates in major cities like Beijing, Shanghai, Guangzhou, and Shenzhen aims to stimulate the housing market, with the new rates at historical lows of 2.6% for first-time buyers [2] Group 2 - The humanoid robot sector has gained renewed attention in the A-share market, with significant investment interest from private equity firms, as the industry is expected to transition from the concept phase to mass production by 2025 [3] - The domestic computing power industry is experiencing a surge in interest, with stocks related to computing power, cloud computing, and AI showing over 10% growth from February to April, driven by strong demand and favorable policies [4] - In the past month, 370 A-share companies have announced share repurchase and increase plans, with a total repurchase amount reaching approximately 681.94 billion yuan [4] Group 3 - SAIC's mobility brand, Xiangdao, has completed over 1.3 billion yuan in Series C financing, marking the largest single financing in the domestic mobility sector in three years, and plans to establish a Robotaxi fleet by 2026 [5] - Xidi Technology has submitted a listing application to the Hong Kong Stock Exchange, indicating a growing trend of tech companies seeking public listings [6] - CITIC Bank plans to establish a wholly-owned subsidiary with a capital of 10 billion yuan to enhance support for technology innovation enterprises and the private economy [10]

国科恒泰：四位股东拟合计减持不超4.7%公司股份 金十数据5月8日讯，国科恒泰公告称，股东国丰鼎嘉、国科鼎奕、国科瑞鼎、国科嘉和金源拟合计减持 不超过4.7%的公司股份。 ...

特别风险提示： 1、持有国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"或"本 公司"）股份 13,634,656 股（占公司总股本比例 2.8973%，占公司剔除回购股份 后总股本的 2.9199%）的股东国科嘉和（北京）投资管理有限公司—苏州国丰鼎 嘉创业投资合伙企业（有限合伙）（以下简称"国丰鼎嘉"）计划在本公告披露 之日起 15 个交易日后的 3 个月内，以集中竞价或大宗交易方式合计减持本公司 股份不超过 6,911,501 股，减持比例不超过公司总股本的 1.4801%（公司总股本 以剔除公司回购股份后的股份数量 466,964,140 股为计算依据，下同）。 2、持有公司股份 4,791,129 股（占公司总股本比例 1.0181%，占公司剔除回 购股份后总股本的 1.0260%）的股东西藏国科鼎奕投资中心（有限合伙）（以下 简称"国科鼎奕"）计划在本公告披露之日起 15 个交易日后的 3 个月内，以集 中竞价或大宗交易方式合计减持本公司股份不超过 2,428,656 股，减持比例不超 过公司总股本的 0.5201%。 证券代码：301370 证券简称：国科恒泰 公告编号：2025-026 ...

Core Viewpoint - Guoke Hengtai aims to become a leading digital supply chain service provider in the medical device industry in China, focusing on distribution and direct sales of medical devices while offering comprehensive logistics and management services [6][12]. Company Overview - Guoke Hengtai specializes in the distribution and direct sales of medical devices, providing services such as warehousing, logistics, channel management, and hospital SPD (Supply, Processing, and Distribution) operations [6][10]. - The company is expanding from high-value medical consumables into various segments of the medical device market [7]. Key Services - **Warehousing and Logistics Services**: The company connects manufacturers with distributors and healthcare institutions, enhancing efficiency and reducing costs in the supply chain [7][8]. - **Channel Management Services**: Guoke Hengtai offers a one-stop distribution platform, managing the entire lifecycle of distributor relationships to improve communication and reduce management costs [8]. - **Information Management Services**: The company has developed a digital supply chain system with multiple patents and software copyrights, integrating various operational subsystems to enhance efficiency and decision-making [9][12]. - **Hospital SPD Operations**: The SPD model is increasingly adopted by hospitals, allowing for integrated management of medical supplies, which improves operational efficiency and reduces costs [10][11]. Financial Highlights - The company has not reported any need for retrospective adjustments to previous financial data, indicating stability in its financial reporting [13]. - As of April 16, 2024, Guoke Hengtai has repurchased 3,635,860 shares, representing 0.77% of its total share capital, with a total transaction amount of approximately 50.09 million yuan [15].

Financial Performance - The company's total revenue for Q1 2025 was 1.738 billion yuan, an increase of 23.9472 million yuan or 1.40% compared to the same period last year [1] - The net profit attributable to shareholders was -8.9525 million yuan, a decrease of 36.558 million yuan or 132.43% year-on-year [1] - The net cash inflow from operating activities was 398 million yuan, an increase of 160 million yuan or 66.97% compared to the same period last year [1] Key Financial Ratios - The latest debt-to-asset ratio is 62.06%, an increase of 0.67 percentage points from the previous quarter, but a decrease of 1.83 percentage points year-on-year [3] - The latest gross profit margin is 9.27%, a decrease of 1.50 percentage points from the previous quarter and a decrease of 1.25 percentage points year-on-year [3] - The latest return on equity (ROE) is -0.36%, a decrease of 1.48 percentage points compared to the same period last year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is -0.02 yuan, a decrease of 0.08 yuan or 133.33% year-on-year [3] - The total asset turnover ratio is 0.26 times, an increase of 0.02 times or 7.29% year-on-year [3] - The inventory turnover ratio is 0.58 times, remaining flat compared to the same period last year, with a year-on-year increase of 0.24 times [3] Shareholder Structure - The number of shareholders is 18,500, with the top ten shareholders holding 318 million shares, accounting for 67.67% of the total share capital [3] - The largest shareholder is 东方科仪控股集团有限公司, holding 30.13% of the shares [3]

证券代码：301370 证券简称：国科恒泰 公告编号：2025-024 国科恒泰（北京）医疗科技股份有限公司 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"本公司"或"公司"） 第三届董事会第三十九次会议决定于 2025 年 5 月 16 日（星期五）召开 2024 年年度 股东大会，现将本次会议有关事项通知如下： 一、召开会议的基本情况 1、会议届次：2024 年年度股东大会。 2、召集人：公司董事会。公司第三届董事会第三十九次会议决议召开本次股东 大会。 3、会议召开的合法、合规性：本次股东大会会议召集程序、召开符合有关法律、 行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开日期和时间： （1）会议召开的时间：2025年5月16日（星期五）下午15:00 （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的时间为2025年5月16日上午 9:15-9:25，9:30-11:30，下午13:00-15:00。 通过深圳证券交易所互联网系统投票的 ...